Two drugs from the same family, two different answers at the pharmacy counter. Pregabalin (Lyrica) is a federal Schedule V controlled substance; gabapentin (Neurontin) is not federally controlled, yet in some states it is scheduled or tracked anyway. That patchwork explains the odd refill rules and the extra questions.
Federal level: the Neurontin label states gabapentin “is not a controlled substance,” while the Lyrica label states “LYRICA is a Schedule V controlled substance.” State level: a few states schedule gabapentin or require it to be reported to prescription monitoring programs. Safety level: the FDA warned in 2019 that both drugs can cause serious breathing problems in people with respiratory risk factors.
If you are here because your pharmacy asked for ID, limited a refill, or told you your state treats gabapentin differently, nothing is wrong with your prescription. The rules vary with where the prescription is written and filled.
Federal status: what each label says
Section 9.1 of the Neurontin label is headed “Controlled Substance” and reads: “NEURONTIN contains gabapentin, which is not a controlled substance.” Section 9.1 of the Lyrica label says: “LYRICA is a Schedule V controlled substance.” Schedule V is the lowest of the five federal schedules, covering drugs with lower abuse potential relative to higher schedules and accepted medical use.
| Gabapentin (Neurontin) | Pregabalin (Lyrica) | |
|---|---|---|
| Federal schedule per the label | Not a controlled substance | Schedule V |
| Abuse and dependence section | Misuse and abuse reported postmarketing, most in people with polysubstance abuse histories; abuse potential “has not been evaluated in human studies” | Recreational-user study: single high dose rated “good drug effect,” “high” and “liking” similarly to diazepam; euphoria reported by 4% of treated patients vs. 1% on placebo |
| Withdrawal language | Symptoms after abrupt discontinuation described, including anxiety, insomnia, nausea, pain, sweating | After abrupt or rapid discontinuation some patients reported insomnia, nausea, headache or diarrhea, with anxiety and sweating in postmarketing reports |
| Breathing warning | Respiratory depression with opioids, other CNS depressants or lung impairment | Respiratory depression is a labeled warning with concomitant CNS depressants or underlying respiratory impairment |
Why pregabalin and not gabapentin?
This is the question behind many searches, and the honest answer has two parts. The Lyrica label contains abuse data that a scheduling decision could rely on: the recreational-user study comparing pregabalin with diazepam, and the euphoria figure. The Neurontin label has no equivalent human abuse study; it states that the abuse potential of gabapentin has not been evaluated in human studies. Beyond that, the sources we opened do not include the DEA’s own explanation of why the two were scheduled differently, so we do not guess at the regulatory history. What the labels show is that gabapentin misuse and abuse are documented even without federal control.
State rules: a patchwork that has changed
A 2022 paper in the Journal of General Internal Medicine (PMC9585149) reviewed state actions between August 2016 and July 2018: Kentucky, Tennessee and West Virginia classified gabapentin as Schedule V, and nine states (Kansas, Massachusetts, Minnesota, Nebraska, New Jersey, North Dakota, Ohio, Virginia and Wyoming) required it to be reported to their prescription drug monitoring programs. The paper lists policy start dates in 2017 and 2018 for these actions. In the Medicare Part D data it analyzed, Schedule V classification was associated with a reduction of about 8.4 days of gabapentin supplied per enrollee per year, compared with about 1 day for PDMP reporting.
That snapshot is old. Laws have moved since: the Code of Virginia now lists gabapentin among Schedule V substances (§ 54.1-3454, the page we opened on October 30, 2026), and secondary sources report that more states, including Alabama and North Dakota, have scheduled it, while disagreeing on a few others. We could not confirm a single authoritative national list from a government source, so the safe step is to ask the pharmacist, or check your state board of pharmacy or PDMP website.
Depending on the state, scheduling can mean prescriptions that expire sooner, limits on refills, or required prescription-monitoring checks by the prescriber and pharmacist. Those are state and pharmacy-practice details and can differ between pharmacies. They do not change the medicine itself.
What this can look like at the counter
- You are asked for photo ID when picking up gabapentin in a state that schedules it.
- A refill is refused before the expected date, or the prescription is valid for a shorter period.
- The pharmacist calls the prescriber to confirm the quantity.
- The same prescription is filled without comment in another state.
- Pregabalin behaves like other Schedule V drugs, with controlled-substance processes at any pharmacy in the country.
None of these is an accusation. Pharmacies apply the strictest rule that governs the prescription. If a refill is blocked, ask the pharmacy what the earliest allowed date is and have the prescriber send a new prescription if needed. Do not stretch a supply by skipping doses without checking; our guide to stopping gabapentin suddenly explains why running out abruptly is a safety issue.
The safety issue that does not depend on scheduling
Schedule status describes legal handling, not how dangerous a drug is. On December 19, 2019, the FDA posted a Drug Safety Communication warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. It named opioid pain medicines and other drugs that depress the central nervous system, conditions such as chronic obstructive pulmonary disease, and older age. FDA required new warnings in the prescribing information and required manufacturers to run trials on abuse potential, particularly with opioids, because misuse of these products together is increasing (FDA communication).
The Neurontin label now includes respiratory depression among its warnings and describes reports of life-threatening or fatal respiratory depression when taken with opioids or other CNS depressants, or with underlying respiratory impairment. Symptoms FDA lists include confusion, unusual dizziness, extreme sleepiness, slowed or shallow breathing, unresponsiveness and bluish lips or fingers. Those call for immediate medical attention. Our pages on gabapentin and breathing problems and drowsiness, breathing risk and tapering go deeper.
What each drug is approved for
The FDA’s 2019 communication notes that gabapentinoids are approved to treat a variety of conditions including partial seizures and nerve pain from spinal cord injury, shingles and diabetes, with other approved uses including fibromyalgia and restless legs syndrome, and that gabapentin was first approved in 1993 and pregabalin in 2004. The uses sit on different labels, so a person taking gabapentin for an off-label purpose, which is common, may find the pharmacy more cautious than for an approved use. Our article on what gabapentin is used for separates approved from off-label uses.
What the Neurontin label says about misuse
The label states that gabapentin misuse and abuse have been reported in the postmarketing setting and published literature, that most of the people described had a history of polysubstance abuse, and that some were taking higher than recommended doses for unapproved uses. It asks prescribers to carefully evaluate patients for a history of drug abuse and observe them for signs of misuse such as self-dose escalation and drug-seeking behavior. The label also says gabapentin does not exhibit affinity for benzodiazepine, opioid or cannabinoid 1 receptor sites. This is the background to why a pharmacy might ask questions even when no law requires it: the labeled advice to watch for misuse applies to every prescription.
Stopping is its own safety issue
Because both drugs are labeled with discontinuation symptoms, a refill problem can become a medical one. The Neurontin label describes symptoms after abrupt discontinuation including anxiety, insomnia, nausea, pain, sweating, tremor, headache, dizziness and malaise, and states that the dependence potential of gabapentin has not been evaluated in human studies. The Lyrica label reports insomnia, nausea, headache or diarrhea after abrupt or rapid discontinuation in clinical studies. If a pharmacy delay or a state rule threatens a gap in supply, call the prescriber that day instead of rationing; they can send a new prescription or advise on a safe step down.
Questions to ask the prescriber or pharmacist
- Is gabapentin or pregabalin regulated differently in this state, and does that affect refills or travel?
- Do any of my other medicines, such as opioids, benzodiazepines, sleep aids or muscle relaxants, add to the breathing and sedation risk?
- Do I have lung disease, sleep apnea or kidney problems that change the risk?
- If I travel, what do I need to carry or ask about? Rules differ between states, and international rules can differ again.
- Why was this drug chosen for my condition? See what gabapentin is used for.
Common misconceptions
“Not controlled means harmless.” The label itself records misuse and abuse, and FDA has documented breathing risk.
“Schedule V means it is a narcotic.” Pregabalin’s label states it is not known to be active at receptor sites associated with drugs of abuse; the schedule reflects regulatory judgment about misuse potential, not a classification as an opioid.
“I can switch from Neurontin to Lyrica if my pharmacy gets strict.” They are different drugs with different labels, indications and side effects, and any change is a prescriber decision.
Sources
- DailyMed: Neurontin label
- DailyMed: Lyrica label
- FDA Drug Safety Communication, 12/19/2019
- J Gen Intern Med 2022: State restrictions on gabapentin and Medicare prescribing
- Code of Virginia § 54.1-3454 (Schedule V)
Evidence checked October 30, 2026. State law changes often; confirm current rules with your pharmacist or state board of pharmacy.